Peter J Schwartz

List of Publications by Year
in descending order

502 papers	63,687 citations	126 h-index	242 g-index
528 all docs	528 docs citations	528 times ranked	24313 citing authors

558

893

#	Article	IF	Citations
1	Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet, The, 1998, 351, 478-484.	13.7	2,791
2	Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genetics, 1996, 12, 17-23.	21.4	1,663
3	Genotype-Phenotype Correlation in the Long-QT Syndrome. Circulation, 2001, 103, 89-95.	1.6	1,641
4	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm, 2013, 10, 1932-1963.	0.7	1,587
5	CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism. Cell, 2004, 119, 19-31.	28.9	1,403
6	Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet, The, 1996, 348, 7-12.	13.7	1,345
7	Risk Stratification in the Long-QT Syndrome. New England Journal of Medicine, 2003, 348, 1866-1874.	27.0	1,314
8	Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina. JAMA - Journal of the American Medical Association, 2002, 288, 701.	7.4	1,218
9	Spectrum of Mutations in Long-QT Syndrome Genes. Circulation, 2000, 102, 1178-1185.	1.6	1,157
10	Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet, The, 1997, 349, 667-674.	13.7	1,041
11	The long Q-T syndrome. American Heart Journal, 1975, 89, 378-390.	2.7	911
12	Heart-Rate Profile during Exercise as a Predictor of Sudden Death. New England Journal of Medicine, 2005, 352, 1951-1958.	27.0	875
13	Prevalence of the Congenital Long-QT Syndrome. Circulation, 2009, 120, 1761-1767.	1.6	855
14	Low Penetrance in the Long-QT Syndrome. Circulation, 1999, 99, 529-533.	1.6	783
15	Effectiveness and Limitations of Î²-Blocker Therapy in Congenital Long-QT Syndrome. Circulation, 2000, 101, 616-623.	1.6	783
16	Recommendations for interpretation of 12-lead electrocardiogram in the athlete. European Heart Journal, 2010, 31, 243-259.	2.2	730
17	Influence of the Genotype on the Clinical Course of the Long-QT Syndrome. New England Journal of Medicine, 1998, 339, 960-965.	27.0	728
18	Task Force on Sudden Cardiac Death of the European Society of Cardiology. European Heart Journal, 2001, 22, 1374-1450.	2.2	699

#	Article	IF	Citations
19	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011, 13, 1077-1109.	1.7	699
20	Long QT Syndrome Patients With Mutations of the SCN5A and HERG Genes Have Differential Responses to Na ⁺ Channel Blockade and to Increases in Heart Rate. Circulation, 1995, 92, 3381-3386.	1.6	689
21	Prolongation of the QT Interval and the Sudden Infant Death Syndrome. New England Journal of Medicine, 1998, 338, 1709-1714.	27.0	672
22	Pathophysiology and Prevention of Atrial Fibrillation. Circulation, 2001, 103, 769-777.	1.6	670
23	Baroreflex Sensitivity and Heart Rate Variability in the Identification of Patients at Risk for Life-Threatening Arrhythmias. Circulation, 2001, 103, 2072-2077.	1.6	619
24	Idiopathic long QT syndrome: Progress and questions. American Heart Journal, 1985, 109, 399-411.	2.7	605
25	Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome. Circulation, 2004, 109, 1826-1833.	1.6	600
26	Multiple Mechanisms in the Long-QT Syndrome. Circulation, 1996, 94, 1996-2012.	1.6	543
27	Association of Long QT Syndrome Loci and Cardiac Events Among Patients Treated With Î²-Blockers. JAMA - Journal of the American Medical Association, 2004, 292, 1341.	7.4	538
28	Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes. Circulation, 2002, 105, 1943-1948.	1.6	514
29	Electrical alternation of the T-wave: Clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. American Heart Journal, 1975, 89, 45-50.	2.7	504
30	ECG T-Wave Patterns in Genetically Distinct Forms of the Hereditary Long QT Syndrome. Circulation, 1995, 92, 2929-2934.	1.6	501
31	Long-QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 868-877.	4.8	498
32	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace, 2013, 15, 1389-1406.	1.7	494
33	Clinical and Genetic Heterogeneity of Right Bundle Branch Block and ST-Segment Elevation Syndrome. Circulation, 2000, 102, 2509-2515.	1.6	490
34	Prevalence of Long-QT Syndrome Gene Variants in Sudden Infant Death Syndrome. Circulation, 2007, 115, 361-367.	1.6	472
35	Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nature Genetics, 2013, 45, 1044-1049.	21.4	467
36	A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10613-10618.	7.1	466

#	Article	IF	Citations
37	Age- and Sex-Related Differences in Clinical Manifestations in Patients With Congenital Long-QT Syndrome. Circulation, 1998, 97, 2237-2244.	1.6	451
38	Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. European Heart Journal, 2011, 32, 847-855.	2.2	444
39	Genetic Testing in the Long QT Syndrome. JAMA - Journal of the American Medical Association, 2005, 294, 2975.	7.4	413
40	Spectrum of ST-Tâ€“Wave Patterns and Repolarization Parameters in Congenital Long-QT Syndrome. Circulation, 2000, 102, 2849-2855.	1.6	409
41	Left Cardiac Sympathetic Denervation for Catecholaminergic Polymorphic Ventricular Tachycardia. New England Journal of Medicine, 2008, 358, 2024-2029.	27.0	377
42	Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-goâ€“Related Gene Potassium Channel. Circulation, 2002, 105, 794-799.	1.6	370
43	Long QT Syndrome in Adults. Journal of the American College of Cardiology, 2007, 49, 329-337.	2.8	369
44	Risk stratification for sudden cardiac death: current status and challenges for the future. European Heart Journal, 2014, 35, 1642-1651.	2.2	341
45	A Molecular Link between the Sudden Infant Death Syndrome and the Long-QT Syndrome. New England Journal of Medicine, 2000, 343, 262-267.	27.0	340
46	The Jervell and Lange-Nielsen Syndrome. Circulation, 2006, 113, 783-790.	1.6	331
47	Calmodulin Mutations Associated With Recurrent Cardiac Arrest in Infants. Circulation, 2013, 127, 1009-1017.	1.6	331
48	Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. American Journal of Cardiology, 1976, 37, 1034-1040.	1.6	319
49	Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Human Molecular Genetics, 1995, 4, 1603-1607.	2.9	316
50	Evidence for a Cardiac Ion Channel Mutation Underlying Drugâ€Induced QT Prolongation and Lifeâ€Threatening Arrhythmias. Journal of Cardiovascular Electrophysiology, 2000, 11, 691-696.	1.7	312
51	Long QT Syndrome and Pregnancy. Journal of the American College of Cardiology, 2007, 49, 1092-1098.	2.8	299
52	QTc Behavior During Exercise and Genetic Testing for the Long-QT Syndrome. Circulation, 2011, 124, 2181-2184.	1.6	299
53	Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Parts I and II. Circulation, 1999, 99, 518-528.	1.6	295
54	Multiple Mechanisms of Na ⁺ Channelâ€“ Linked Long-QT Syndrome. Circulation Research, 1996, 78, 916-924.	4.5	285

#	Article	IF	Citations
55	Vagus Nerve Stimulation for the Treatment of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 149-158.	2.8	283
56	The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. European Heart Journal, 2013, 34, 3109-3116.	2.2	282
57	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nature Genetics, 2014, 46, 826-836.	21.4	281
58	High Efficacy of Î²-Blockers in Long-QT Syndrome Type 1. Circulation, 2009, 119, 215-221.	1.6	274
59	Impact of Genetics on the ClinicalÂManagementÂof Channelopathies. Journal of the American College of Cardiology, 2013, 62, 169-180.	2.8	271
60	Exercise-Induced Increase in Baroreflex Sensitivity Predicts Improved Prognosis After Myocardial Infarction. Circulation, 2002, 106, 945-949.	1.6	269
61	Nervous activity of afferent cardiac sympathetic fibres with atrial and ventricular endings. Journal of Physiology, 1973, 229, 457-469.	2.9	268
62	Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals. Journal of the American College of Cardiology, 2011, 57, 51-59.	2.8	268
63	Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. Nature Genetics, 1994, 8, 141-147.	21.4	263
64	Long term vagal stimulation in patients with advanced heart failure First experience in man. European Journal of Heart Failure, 2008, 10, 884-891.	7.1	262
65	Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?. Circulation, 2010, 122, 1272-1282.	1.6	261
66	A Cardiocardiac Sympathovagal Reflex in the Cat. Circulation Research, 1973, 32, 215-220.	4.5	260
67	The long QT syndrome. Current Problems in Cardiology, 1997, 22, 297-351.	2.4	259
68	Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. Journal of the American College of Cardiology, 2003, 42, 103-109.	2.8	257
69	Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome. Circulation, 2008, 117, 2184-2191.	1.6	255
70	Gain-of-function mutation S422L in the KCNJ8-encoded cardiac KATP channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm, 2010, 7, 1466-1471.	0.7	250
71	Electrocardiographic Features in Andersen-Tawil Syndrome Patients With KCNJ2 Mutations. Circulation, 2005, 111, 2720-2726.	1.6	248
72	The Elusive Link Between LQT3 and Brugada Syndrome. Circulation, 2000, 102, 945-947.	1.6	243

#	Article	IF	Citations
73	NOS1AP Is a Genetic Modifier of the Long-QT Syndrome. Circulation, 2009, 120, 1657-1663.	1.6	241
74	Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2015, 131, 2185-2193.	1.6	238
75	Influence of Pregnancy on the Risk for Cardiac Events in Patients With Hereditary Long QT Syndrome. Circulation, 1998, 97, 451-456.	1.6	235
76	Not All Beta-Blockers Are Equal in the Management of Long QT Syndrome Types 1 and 2. Journal of the American College of Cardiology, 2012, 60, 2092-2099.	2.8	234
77	KCNH2 -K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome. Circulation, 2005, 112, 1251-1258.	1.6	228
78	Predicting the Unpredictable. Journal of the American College of Cardiology, 2016, 67, 1639-1650.	2.8	227
79	Transient outward current (Ito) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm, 2011, 8, 1024-1032.	0.7	226
80	Clinical neurocardiology defining the value of neuroscienceâ€based cardiovascular therapeutics. Journal of Physiology, 2016, 594, 3911-3954.	2.9	222
81	Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. American Journal of Cardiology, 1999, 84, 876-879.	1.6	219
82	Heart rate turbulence-based predictors of fatal and nonfatal cardiac arrest (The autonomic tone and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	219
83	Congenital long QT syndrome. Orphanet Journal of Rare Diseases, 2008, 3, 18.	2.7	213
84	Mortality in Patients After a Recent Myocardial Infarction. Circulation, 2004, 109, 990-996.	1.6	210
85	Cardiac sympathetic innervation and the sudden infant death syndrome. American Journal of Medicine, 1976, 60, 167-172.	1.5	207
86	The congenital long QT syndromes from genotype to phenotype: clinical implications. Journal of Internal Medicine, 2006, 259, 39-47.	6.0	201
87	Spectrum and Prevalence of Mutations Involving BrS1- Through BrS12-Susceptibility Genes in a Cohort of Unrelated Patients Referred for Brugada Syndrome Genetic Testing. Journal of the American College of Cardiology, 2012, 60, 1410-1418.	2.8	193
88	Guidelines for the interpretation of the neonatal electrocardiogram. European Heart Journal, 2002, 23, 1329-1344.	2.2	184
89	The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. Journal of Clinical Investigation, 2008, 118, 2219-29.	8.2	184
90	Comparison of baroreflex sensitivity and heart period variability after myocardial infarction. Journal of the American College of Cardiology, 1989, 14, 1511-1518.	2.8	183

#	Article	IF	Citations
91	Cardiac Sodium Channel Dysfunction in Sudden Infant Death Syndrome. Circulation, 2007, 115, 368-376.	1.6	183
92	Cardiac sympathetic denervation to prevent life-threatening arrhythmias. Nature Reviews Cardiology, 2014, 11, 346-353.	13.7	183
93	Neural mechanisms in life-threatening arrhythmias. American Heart Journal, 1980, 100, 705-715.	2.7	181
94	Phenotypic Variability and Unusual Clinical Severity of Congenital Long-QT Syndrome in a Founder Population. Circulation, 2005, 112, 2602-2610.	1.6	179
95	Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. Journal of the American College of Cardiology, 1994, 23, 296-301.	2.8	177
96	Age-Gender Influence on the Rate-Corrected QT Interval and the QT-Heart Rate Relation in Families With Genotypically Characterized Long QT Syndrome. Journal of the American College of Cardiology, 1997, 29, 93-99.	2.8	177
97	Effects of unilateral stellate ganglion blockade on the arrhythmias associated with coronary occlusion. American Heart Journal, 1976, 92, 589-599.	2.7	174
98	Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 652-659.	4.8	174
99	Cellular Dysfunction of LQT5-MinK Mutants: Abnormalities of IKs, IKr and Trafficking in Long QT Syndrome. Human Molecular Genetics, 1999, 8, 1499-1507.	2.9	170
100	Novel Calmodulin Mutations Associated With Congenital Arrhythmia Susceptibility. Circulation: Cardiovascular Genetics, 2014, 7, 466-474.	5.1	165
101	The genetics underlying acquired long QT syndrome: impact for genetic screening. European Heart Journal, 2016, 37, 1456-1464.	2.2	164
102	Vagal Stimulation, Through its Nicotinic Action, Limits Infarct Size and the Inflammatory Response to Myocardial Ischemia and Reperfusion. Journal of Cardiovascular Pharmacology, 2011, 58, 500-507.	1.9	163
103	Prevention of Sudden Cardiac Death After a First Myocardial Infarction by Pharmacologic or Surgical Antiadrenergic Interventions. Journal of Cardiovascular Electrophysiology, 1992, 3, 2-16.	1.7	162
104	Clinical Aspects of Type 3 Long-QT Syndrome. Circulation, 2016, 134, 872-882.	1.6	162
105	Ambulatory Electrocardiogramâ€Based Tracking of T Wave Alternans in Postmyocardial Infarction Patients to Assess Risk of Cardiac Arrest or Arrhythmic Death. Journal of Cardiovascular Electrophysiology, 2003, 14, 705-711.	1.7	160
106	Real-Life Observations of Clinical Outcomes With Rhythm- and Rate-Control Therapies for Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 58, 493-501.	2.8	159
107	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm, 2013, 10, e85-e108.	0.7	159
108	Molecular diagnosis in a child with sudden infant death syndrome. Lancet, The, 2001, 358, 1342-1343.	13.7	157

#	Article	IF	Citations
109	The Common Long-QT Syndrome Mutation KCNQ1/A341V Causes Unusually Severe Clinical Manifestations in Patients With Different Ethnic Backgrounds. Circulation, 2007, 116, 2366-2375.	1.6	157
110	Baroreflex Sensitivity and Its Evolution During the First Year After Myocardial Infarction. Journal of the American College of Cardiology, 1988, 12, 629-636.	2.8	155
111	Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions. Heart Failure Reviews, 2011, 16, 195-203.	3.9	151
112	Evaluation of the Spatial Aspects of T-Wave Complexity in the Long-QT Syndrome. Circulation, 1997, 96, 3006-3012.	1.6	151
113	Mortality in the Survival With ORal D-Sotalol (SWORD) Trial: Why Did Patients Die? 11This work was supported by a grant from Bristol-Myers Squibb, Princeton, New Jersey.. American Journal of Cardiology, 1998, 81, 869-876.	1.6	150
114	Differential Response to Na ⁺ Channel Blockade, Î²-Adrenergic Stimulation, and Rapid Pacing in a Cellular Model Mimicking the SCN5A and HERG Defects Present in the Long-QT Syndrome. Circulation Research, 1996, 78, 1009-1015.	4.5	148
115	Inherited cardiac arrhythmias. Nature Reviews Disease Primers, 2020, 6, 58.	30.5	146
116	Baroreflex Sensitivity Predicts Long-Term Cardiovascular Mortality After Myocardial Infarction Even in Patients With Preserved Left Ventricular Function. Journal of the American College of Cardiology, 2007, 50, 2285-2290.	2.8	143
117	THE ROLE OF THE AUTONOMIC NERVOUS SYSTEM IN SUDDEN CORONARY DEATH. Annals of the New York Academy of Sciences, 1982, 382, 162-180.	3.8	141
118	Long QT Syndromeâ€“Associated Mutations in Intrauterine Fetal Death. JAMA - Journal of the American Medical Association, 2013, 309, 1473.	7.4	140
119	A Recessive Variant of the Romano-Ward Long-QT Syndrome?. Circulation, 1998, 97, 2420-2425.	1.6	139
120	Sympatheticâ€“parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Failure Reviews, 2011, 16, 101-107.	3.9	137
121	Update of the guidelines on sudden cardiac death of the European Society of Cardiology. European Heart Journal, 2003, 24, 13-15.	2.2	135
122	Heart rate variability before and after myocardial infarction in conscious dogs at high and low risk of sudden death. Journal of the American College of Cardiology, 1990, 16, 978-985.	2.8	134
123	Genetic and molecular basis of cardiac arrhythmias Impact on clinical management. European Heart Journal, 1999, 20, 174-195.	2.2	134
124	Long-QT Syndrome After Age 40. Circulation, 2008, 117, 2192-2201.	1.6	134
125	Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Part III. Circulation, 1999, 99, 674-681.	1.6	131
126	Rationale and study design of the INcrease Of Vagal TonE in Heart Failure study: INOVATE-HF. American Heart Journal, 2012, 163, 954-962.e1.	2.7	130

#	Article	IF	Citations
127	Summary of Recommendations. Europace, 2002, 4, 3-18.	1.7	124
128	Identification of Cadherin 2 (CDH2) Mutations in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	123
129	Torsade de Pointes. Drugs, 1994, 47, 51-65.	10.9	122
130	Cost-effectiveness of neonatal ECG screening for the long QT syndrome. European Heart Journal, 2006, 27, 1824-1832.	2.2	121
131	Survival with oral d-Sotalol in patients with left ventricular dysfunction after myocardial infarction: Rationale, design, and methods (the SWORD trial). American Journal of Cardiology, 1995, 75, 1023-1027.	1.6	116
132	Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. European Heart Journal, 2019, 40, 2964-2975.	2.2	116
133	The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity. American Heart Journal, 1985, 109, 937-948.	2.7	113
134	Sudden death and the idiopathic long Q-T syndrome. American Journal of Medicine, 1979, 66, 6-7.	1.5	111
135	How Really Rare Are Rare Diseases?:. Journal of Cardiovascular Electrophysiology, 2003, 14, 1120-1121.	1.7	110
136	Risk Factors for Recurrent Syncope and Subsequent Fatal or Near-Fatal Events in Children and Adolescents With Long QT Syndrome. Journal of the American College of Cardiology, 2011, 57, 941-950.	2.8	110
137	Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. Cardiovascular Research, 2017, 113, 531-541.	3.8	110
138	Cardiac Arrhythmias Elicited by Interaction Between Acute Myocardial Ischemia and Sympathetic Hyperactivity. Journal of Cardiovascular Pharmacology, 1981, 3, 1251-1259.	1.9	109
139	Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. Cardiovascular Research, 2015, 106, 520-529.	3.8	108
140	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace, 2022, 24, 1307-1367.	1.7	108
141	25th Anniversary of the International Long-QT Syndrome Registry. Circulation, 2005, 111, 1199-1201.	1.6	106
142	Are gender differences in QTc present at birth?. American Journal of Cardiology, 1995, 75, 1277-1278.	1.6	105
143	Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone. Journal of the American College of Cardiology, 2000, 35, 1263-1275.	2.8	104
144	A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na 1.5 and K 4.3 channel currents. Heart Rhythm, 2012, 9, 760-769.	0.7	104

#	Article	IF	Citations
145	Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. European Heart Journal, 2018, 39, 1446-1455.	2.2	100
146	Neural Control of Heart Rate Is an Arrhythmia Risk Modifier in Long QT Syndrome. Journal of the American College of Cardiology, 2008, 51, 920-929.	2.8	99
147	THE RATIONALE AND THE ROLE OF LEFT STELLECTOMY FOR THE PREVENTION OF MALIGNANT ARRHYTHMIAS. Annals of the New York Academy of Sciences, 1984, 427, 199-221.	3.8	98
148	Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failureâ˜†. European Journal of Heart Failure, 2008, 10, 550-555.	7.1	98
149	The RecordAF Study: Design, Baseline Data, and Profile of Patients According to Chosen Treatment Strategy for Atrial Fibrillation. American Journal of Cardiology, 2010, 105, 687-693.	1.6	98
150	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. European Heart Journal, 2019, 40, 2953-2961.	2.2	96
151	Cardiac potassium channel dysfunction in sudden infant death syndrome. Journal of Molecular and Cellular Cardiology, 2008, 44, 571-581.	1.9	95
152	FGF12 is a candidate Brugada syndrome locus. Heart Rhythm, 2013, 10, 1886-1894.	0.7	94
153	Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction. Journal of the American College of Cardiology, 1993, 22, 1327-1334.	2.8	91
154	All LQT3 patients need an ICD: True or false?. Heart Rhythm, 2009, 6, 113-120.	0.7	91
155	Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. Heart Rhythm, 2016, 13, 1274-1282.	0.7	89
156	Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1748-H1756.	3.2	88
157	Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: The surgical supraclavicular approach to cervicothoracic sympathectomy. Heart Rhythm, 2010, 7, 1161-1165.	0.7	88
158	Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: Clinical correlates and the effect of rhythm-control therapy. American Heart Journal, 2012, 163, 887-893.	2.7	88
159	New Mutations in the KVLQT1 Potassium Channel That Cause Long-QT Syndrome. Circulation, 1998, 97, 1264-1269.	1.6	87
160	Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. Journal of the American College of Cardiology, 1993, 22, 283-290.	2.8	85
161	A Novel Disease Gene for Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 1098-1107.	4.8	84
162	Baroreflex sensitivity, but not heart rate variability, is reduced in patients with life-threatening ventricular arrhythmias long after myocardial infarction. American Heart Journal, 1995, 130, 473-480.	2.7	83

#	Article	IF	Citations
163	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
164	Clinical Implications for Patients With Long QT Syndrome Who Experience a Cardiac Event During Infancy. Journal of the American College of Cardiology, 2009, 54, 832-837.	2.8	82
165	Dispersion of ventricular repolarization in the long QT syndrome. American Journal of Cardiology, 1991, 68, 614-620.	1.6	80
166	Homozygous Deletion in KVLQT1 Associated With Jervell and Lange-Nielsen Syndrome. Circulation, 1999, 99, 1344-1347.	1.6	80
167	Electrocardiographic Prediction of Abnormal Genotype in Congenital Long QT Syndrome: Experience in 101 Related Family Members. Journal of Cardiovascular Electrophysiology, 2001, 12, 455-461.	1.7	79
168	Arrhythmogenic Calmodulin Mutations Disrupt Intracellular Cardiomyocyte Ca 2+ Regulation by Distinct Mechanisms. Journal of the American Heart Association, 2014, 3, e000996.	3.7	79
169	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm, 2022, 19, e1-e60.	0.7	78
170	Cellular Mechanisms of Early Afterdepolarizations. Annals of the New York Academy of Sciences, 1992, 644, 23-32.	3.8	77
171	Prevalent Low-Frequency Oscillation of Heart Rate. Circulation, 2004, 110, 1183-1190.	1.6	77
172	The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction. Journal of the American College of Cardiology, 2004, 43, 1211-1216.	2.8	77
173	Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. Heart Rhythm, 2018, 15, 1791-1799.	0.7	77
174	High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study. International Journal of Cardiology, 2011, 147, 124-131.	1.7	76
175	Two cases of sudden unexpected death in epilepsy in a GEFS+ family with an SCN1A mutation. Epilepsia, 2008, 49, 360-365.	5.1	74
176	Mexiletine Shortens the QT Interval in Patients With Potassium Channelâ€“Mediated Type 2 Long QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007280.	4.8	74
177	Reflex responses of sympathetic preganglionic neurones initiated by different cardiovascular receptors in spinal animals. Brain Research, 1974, 68, 215-225.	2.2	72
178	Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with the long QT syndrome. American Journal of Cardiology, 2000, 85, 457-461.	1.6	72
179	Clinical Implications for Affected Parents and Siblings of Probands With Long-QT Syndrome. Circulation, 2001, 104, 557-562.	1.6	71
180	Autonomic Control of Heart Rate and QTÂInterval Variability Influences Arrhythmic Risk in Long QT Syndrome Type 1. Journal of the American College of Cardiology, 2015, 65, 367-374.	2.8	70

#	Article	IF	Citations
181	Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation. International Journal of Cardiology, 2017, 249, 268-273.	1.7	70
182	Do Increases in Markers of Vagal Activity Imply Protection From Sudden Death?. Circulation, 1995, 91, 2516-2519.	1.6	70
183	Location of Mutation in the KCNQ1 and Phenotypic Presentation of Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 2003, 14, 1149-1153.	1.7	69
184	Identification of a KCNQ1 Polymorphism Acting as a Protective Modifier Against Arrhythmic Risk in Long-QT Syndrome. Circulation: Cardiovascular Genetics, 2013, 6, 354-361.	5.1	69
185	From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. European Heart Journal, 2019, 40, 1832-1836.	2.2	69
186	Mechanisms of I _{Ks} suppression in LQT1 mutants. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H3003-H3011.	3.2	68
187	Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm, 2008, 5, 831-836.	0.7	65
188	ATRAMI: a mark in the quest for the prognostic value of autonomic markers. European Heart Journal, 1998, 19, 1593-1595.	2.2	64
189	Rapid Heart Rate Increase at Onset of Exercise Predicts Adverse Cardiac Events in Patients With Coronary Artery Disease. Circulation, 2005, 112, 1959-1964.	1.6	64
190	Baroreflex Sensitivity. Journal of Cardiovascular Electrophysiology, 1995, 6, 761-774.	1.7	63
191	Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine) Tj ETQq1 1 0.784314 rgBT /Over	0.7	63
192	The European Myocardial Infarct Amiodarone Trial (EMIAT). American Journal of Cardiology, 1993, 72, F95-F98.	1.6	60
193	Impaired Baroreflex Sensitivity Is Correlated With Hemodynamic Deterioration of Sustained Ventricular Tachycardia. Journal of the American College of Cardiology, 1997, 29, 568-575.	2.8	59
194	Left cardiac sympathetic denervation in the Netherlands for the treatment of inherited arrhythmia syndromes. Netherlands Heart Journal, 2014, 22, 160-166.	0.8	59
195	AKAP9 Is a Genetic Modifier of Congenital Long-QT Syndrome Type 1. Circulation: Cardiovascular Genetics, 2014, 7, 599-606.	5.1	59
196	Patency of Infarct-Related Artery. Circulation, 1996, 93, 1114-1122.	1.6	59
197	Rationale and objectives for ECG screening in infancy. Heart Rhythm, 2014, 11, 2316-2321.	0.7	57
198	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	2.4	57

#	Article	IF	Citations
199	Does Pregnancy Increase Cardiac Risk for LQT1 Patients With the KCNQ1-A341V Mutation?. Journal of the American College of Cardiology, 2006, 48, 1410-1415.	2.8	56
200	Activation of cardiac vagal receptors during myocardial ischemia. Experientia, 1971, 27, 1423-1424.	1.2	55
201	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	21.4	55
202	Spinal cardiovascular reflexes. Brain Research, 1975, 87, 239-246.	2.2	54
203	Vagal stimulation for heart failure: Background and first in-man study. Heart Rhythm, 2009, 6, S76-S81.	0.7	54
204	Characterization of SEMA3A -Encoded Semaphorin as a Naturally Occurring K v 4.3 Protein Inhibitor and its Contribution to Brugada Syndrome. Circulation Research, 2014, 115, 460-469.	4.5	54
205	Autonomic Modulation for the Management of Patients with Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 619-628.	3.9	54
206	Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine. American Heart Journal, 1992, 124, 883-890.	2.7	53
207	Cutting nerves and saving lives. Heart Rhythm, 2009, 6, 760-763.	0.7	53
208	A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome. International Journal of Cardiology, 2018, 266, 89-94.	1.7	53
209	Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies. Circulation Research, 2019, 125, 653-658.	4.5	53
210	Stillbirths, Sudden Infant Deaths, and Long-QT Syndrome. Circulation, 2004, 109, 2930-2932.	1.6	52
211	Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Rhythm Control Versus Rate Control. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 896-904.	2.2	52
212	Modifier genes for sudden cardiac death. European Heart Journal, 2018, 39, 3925-3931.	2.2	52
213	Vagal Reflexes Following an Exercise Stress Test. Journal of the American College of Cardiology, 2012, 60, 2515-2524.	2.8	51
214	Time- and Rate-Dependent Alterations of the QT Interval Precede the Onset of Torsade de Pointes in Patients With Acquired QT Prolongation fn1fn1This work was performed during Dr. Gilmourâ€™s sabbatical leave in the laboratory of Dr. Schwartz.. Journal of the American College of Cardiology, 1997, 30, 209-217.	2.8	49
215	Vagal Stimulation for Heart Diseases: From Animals to Men - An Example of Translational Cardiology -. Circulation Journal, 2011, 75, 20-27.	1.6	49
216	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Journal of Arrhythmia, 2014, 30, 1-28.	1.2	49

#	Article	IF	Citations
217	Malignant Perinatal Variant of Long-QT Syndrome Caused by a Profoundly Dysfunctional Cardiac Sodium Channel. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 370-378.	4.8	48
218	Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). European Heart Journal, 1998, 19, 85-95.	2.2	47
219	Psychological Stress Preceding Idiopathic Ventricular Fibrillation. Psychosomatic Medicine, 2005, 67, 359-365.	2.0	47
220	Excessive heart rate increase during mild mental stress in preparation for exercise predicts sudden death in the general population. European Heart Journal, 2009, 30, 1703-1710.	2.2	47
221	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace, 2021, 23, 147-148.	1.7	47
222	Cardiac Innervation, Neonatal Electrocardiography, and SIDS.. Annals of the New York Academy of Sciences, 1988, 533, 210-220.	3.8	46
223	Task Force Report:The legal implications of medical guidelinesâ€" a Task Force of the European Society of Cardiology. European Heart Journal, 1999, 20, 1152-1157.	2.2	46
224	Cumulative Experience of Azimilide-Associated Torsades de Pointes Ventricular Tachycardia in the 19 Clinical Studies Comprising the Azimilide Database. Journal of the American College of Cardiology, 2006, 48, 471-477.	2.8	44
225	Reflex Hemodynamic Responses Initiated from the Thoracic Aorta. Circulation Research, 1974, 34, 78-84.	4.5	43
226	Sympathetic activation, ventricular repolarization and Ikrblockade: Implications for the antifibrillatory efficacy of potassium channel blocking agents. Journal of the American College of Cardiology, 1995, 25, 1609-1614.	2.8	43
227	QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. American Heart Journal, 1997, 133, 108-111.	2.7	43
228	T-Wave Amplitude as an Index of Cardiac Sympathetic Activity: A Misleading Concept. Psychophysiology, 1983, 20, 696-701.	2.4	42
229	The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia?. International Journal of Cardiology, 2018, 250, 139-145.	1.7	42
230	A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype-negative long QT syndrome. Heart Rhythm, 2009, 6, 212-218.	0.7	41
231	SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families. Circulation Genomic and Precision Medicine, 2020, 13, e002911.	3.6	41
232	Molecular Biology of the Long QT Syndrome: Impact on Management. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2052-2057.	1.2	40
233	Of founder populations, long QT syndrome, and destiny. Heart Rhythm, 2009, 6, S25-S33.	0.7	40
234	Comparison between invasive and non-invasive measurements of baroreflex sensitivity. Implications for studies on risk stratification after a myocardial infarction. European Heart Journal, 2000, 21, 1522-1529.	2.2	39

#	Article	IF	Citations
235	Management of long QT syndrome. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 346-351.	3.3	39
236	An International Multicenter Evaluation of Type 5 Long QT Syndrome. Circulation, 2020, 141, 429-439.	1.6	39
237	Left stellectomy and denervation supersensitivity in conscious dogs. American Journal of Cardiology, 1982, 49, 1185-1190.	1.6	37
238	Sex Differences in Phenotypic Manifestation and Gene Transmission in the Romano-Ward Syndrome. Annals of the New York Academy of Sciences, 1992, 644, 142-156.	3.8	37
239	Another Role for the Sympathetic Nervous System in the Long QT Syndrome?. Journal of Cardiovascular Electrophysiology, 2001, 12, 500-502.	1.7	37
240	QT Prolongation, Sudden Death, and Sympathetic Imbalance: The Pendulum Swings. Journal of Cardiovascular Electrophysiology, 2001, 12, 1074-1077.	1.7	37
241	Effect of ventricular fibrillation complicating acute myocardial infarction on long-term prognosis: Importance of the site of infarction. American Journal of Cardiology, 1985, 56, 384-389.	1.6	36
242	Pathogenesis and Therapy of the Idiopathic Long QT Syndrome. Annals of the New York Academy of Sciences, 1992, 644, 112-141.	3.8	36
243	Newborn ECG screening to prevent sudden cardiac death. Heart Rhythm, 2006, 3, 1353-1355.	0.7	36
244	Exercise Training-Induced Repolarization Abnormalities Masquerading as Congenital Long QT Syndrome. Circulation, 2020, 142, 2405-2415.	1.6	36
245	Long QT Syndrome Modelling with Cardiomyocytes Derived from Human-induced Pluripotent Stem Cells. Arrhythmia and Electrophysiology Review, 2019, 8, 105-110.	2.4	36
246	Baroreflex Sensitivity as a Cardiac and Arrhythmia Mortality Risk Stratifier. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2602-2613.	1.2	35
247	Multiscale Complexity Analysis of the Cardiac Control Identifies Asymptomatic and Symptomatic Patients in Long QT Syndrome Type 1. PLoS ONE, 2014, 9, e93808.	2.5	35
248	Torsades de pointes following acute myocardial infarction: Evidence for a deadly link with a common genetic variant. Heart Rhythm, 2012, 9, 1104-1112.	0.7	34
249	Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: Implications for the clinical management of LQT3 patients. Heart Rhythm, 2014, 11, 126-132.	0.7	34
250	Mothers with long QT syndrome are at increased risk for fetal death: findings from a multicenter international study. American Journal of Obstetrics and Gynecology, 2020, 222, 263.e1-263.e11.	1.3	34
251	MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes. Cardiovascular Research, 2021, 117, 767-779.	3.8	34
252	Precision Medicine and cardiac channelopathies: when dreams meet reality. European Heart Journal, 2021, 42, 1661-1675.	2.2	34

#	Article	IF	Citations
253	Sympathetic â€" Parasympathetic Interaction and Sudden Death. , 1991, 85 Suppl 1, 305-321.		34
254	Determinants of occurrence and survival after sudden cardiac arrestâ€"A European perspective: The ESCAPE-NET project. Resuscitation, 2018, 124, 7-13.	3.0	33
255	SCN5A mutations in 442 neonates and children: genotypeâ€"phenotype correlation and identification of higher-risk subgroups. European Heart Journal, 2018, 39, 2879-2887.	2.2	33
256	Genetic Mosaicism in Calmodulinopathy. Circulation Genomic and Precision Medicine, 2019, 12, 375-385.	3.6	33
257	The Idiopathic Long Q-T Syndrome. Annals of Internal Medicine, 1983, 99, 561.	3.9	33
258	Do Animal Models Have Clinical Value?. American Journal of Cardiology, 1998, 81, 14D-20D.	1.6	32
259	Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease. International Journal of Cardiology, 2003, 90, 219-227.	1.7	32
260	Efficacy of left cardiac sympathetic denervation has an unforeseen side effect: Medicolegal complications. Heart Rhythm, 2010, 7, 1330-1332.	0.7	32
261	The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. Europace, 2013, 15, 429-436.	1.7	32
262	A comprehensive electrocardiographic, molecular, and echocardiographic study of Brugada syndrome: Validation of the 2013 diagnostic criteria. Heart Rhythm, 2014, 11, 1176-1183.	0.7	32
263	International Triadin Knockout Syndrome Registry. Circulation Genomic and Precision Medicine, 2019, 12, e002419.	3.6	32
264	Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies. Scientific Reports, 2016, 6, 22235.	3.3	31
265	Hemodynamic Effects of a New Inotropic Compound, PST-2744, in Dogs With Chronic Ischemic Heart Failure. Journal of Cardiovascular Pharmacology, 2003, 42, 169-173.	1.9	30
266	Prediction of unexpected sudden death among healthy dogs by a novel marker of autonomic neural activity. Heart Rhythm, 2008, 5, 300-305.	0.7	30
267	Nadolol Block of Nav1.5 Does Not Explain Its Efficacy in the Long QT Syndrome. Journal of Cardiovascular Pharmacology, 2012, 59, 249-253.	1.9	30
268	Efficacy of diltiazem in two experimental feline models of sudden cardiac death. Journal of the American College of Cardiology, 1986, 8, 661-668.	2.8	29
269	Controlling Cardiac Arrhythmias by Lengthening Repolarization: Rationale from Experimental Findings and Clinical Considerations. Annals of the New York Academy of Sciences, 1992, 644, 187-209.	3.8	29
270	Ionic Mechanisms Determining the Timing of Ventricular Repolarization: Significance for Cardiac Arrhythmias. Annals of the New York Academy of Sciences, 1992, 644, 1-22.	3.8	28

#	Article	IF	Citations
271	The Long QT Syndrome. Annals of Noninvasive Electrocardiology, 1998, 3, 63-73.	1.1	28
272	Long QT syndrome, a purely electrical disease? Not anymore. European Heart Journal, 2008, 30, 253-255.	2.2	28
273	Mutation-Specific Risk in Two Genetic Forms of Type 3 Long QT Syndrome. American Journal of Cardiology, 2010, 105, 210-213.	1.6	28
274	Dietary Omega-3 Fatty Acids and Susceptibility to Ventricular Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 553-560.	4.8	28
275	Tumor Necrosis Factor-Î± Predicts Response to Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure. Circulation Journal, 2014, 78, 2232-2239.	1.6	28
276	Remodelling of cardiac sympathetic re-innervation with thoracic spinal cord stimulation improves left ventricular function in a porcine model of heart failure. Europace, 2015, 17, 1875-1883.	1.7	28
277	The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2. International Journal of Cardiology, 2017, 240, 367-371.	1.7	28
278	Channelopathies as Causes of Sudden Cardiac Death. Cardiac Electrophysiology Clinics, 2017, 9, 537-549.	1.7	28
279	For neonatal ECG screening there is no reason to relinquish old Bazettâ€™s correction. European Heart Journal, 2018, 39, 2888-2895.	2.2	28
280	An International Multicenter Cohort Study on Î²-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2022, 145, 333-344.	1.6	28
281	Cardiac sympathetic denervation 100 years later: Jonnesco would have never believed it. International Journal of Cardiology, 2017, 237, 25-28.	1.7	27
282	Autonomic Control of the Heart and Its Clinical Impact. A Personal Perspective. Frontiers in Physiology, 2020, 11, 582.	2.8	26
283	1970â€“2020: 50 years of research on the long QT syndromeâ€”from almost zero knowledge to precision medicine. European Heart Journal, 2021, 42, 1063-1072.	2.2	26
284	Mutation location and I ÂKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. European Heart Journal, 2021, 42, 4743-4755.	2.2	26
285	Role of the Autonomic Nervous System in the Genesis of Early Ischemic Arrhythmias. Journal of Cardiovascular Pharmacology, 1985, 7, S8-S12.	1.9	25
286	Effect of reflex vagal activation on frequency of ventricular premature complexes. American Journal of Cardiology, 1991, 68, 349-354.	1.6	25
287	Sudden cardiac death, founder populations, and mushrooms: What is the link with gold mines and modifier genes?. Heart Rhythm, 2011, 8, 548-550.	0.7	25
288	Cardiac Sympathetic Denervation in Channelopathies. Frontiers in Cardiovascular Medicine, 2019, 6, 27.	2.4	25

#	Article	IF	Citations
289	Long QT Syndrome: Genotype-Phenotype Correlations. , 2004, , 651-659.		25
290	Left Cardiac Sympathetic Denervation for Long QT Syndrome. JACC: Clinical Electrophysiology, 2022, 8, 281-294.	3.2	25
291	Ventricular fibrillation induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity: Effect of nifedipine. American Heart Journal, 1988, 116, 37-43.	2.7	24
292	Clinical Aspects of the Idiopathic Long QT Syndrome. Annals of the New York Academy of Sciences, 1992, 644, 103-111.	3.8	24
293	Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis. PLoS ONE, 2015, 10, e0127213.	2.5	24
294	Reference values of heart rate variability. Heart Rhythm, 2017, 14, 302-303.	0.7	24
295	Genotype Predicts Outcomes in Fetuses and Neonates With Severe Congenital Long QT Syndrome. JACC: Clinical Electrophysiology, 2020, 6, 1561-1570.	3.2	24
296	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Journal of Arrhythmia, 2022, 38, 491-553.	1.2	24
297	Multiple Ionic Mechanisms of Early Afterdepolarizations in Isolated Ventricular Myocytes from Guinea-pig Hearts. Annals of the New York Academy of Sciences, 1992, 644, 33-47.	3.8	23
298	European Sudden Cardiac Arrest network: towards Prevention, Education and New Effective Treatments (ESCAPE-NET). European Heart Journal, 2018, 39, 86-88.	2.2	23
299	Two-to-One AV Block Associated with the Congenital Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 1999, 10, 108-113.	1.7	22
300	Significance of QT dispersion in the long QT syndrome. Progress in Cardiovascular Diseases, 2000, 42, 345-350.	3.1	22
301	QT or Not QT?. New England Journal of Medicine, 2000, 343, 352-356.	27.0	22
302	Heterogeneous Regional Endocardial Repolarization is Associated with Increased Risk for Ischemiaâ€Dependent Ventricular Fibrillation after Myocardial Infarction. Journal of Cardiovascular Electrophysiology, 2003, 14, 873-879.	1.7	22
303	Genotype-specific QT correction for heart rate and the risk of life-threatening cardiac events in adolescents with congenital long-QT syndrome. Heart Rhythm, 2011, 8, 1207-1213.	0.7	22
304	Pharmacological and non-pharmacological management of the congenital long QT syndrome: The rationale. , 2011, 131, 171-177.		22
305	NOS1AP polymorphisms reduce NOS1 activity and interact with prolonged repolarization in arrhythmogenesis. Cardiovascular Research, 2021, 117, 472-483.	3.8	22
306	Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias. European Heart Journal, 2022, 43, 2096-2102.	2.2	22

#	Article	IF	Citations
307	A New Look at Torsades de Pointes. Annals of the New York Academy of Sciences, 1992, 644, 157-177.	3.8	21
308	K+ Channel Blockade in the Prevention of Ventricular Fibrillation in Dogs with Acute Ischemia and Enhanced Sympathetic Activity. Journal of Cardiovascular Pharmacology, 1995, 26, 847-854.	1.9	21
309	Genetic Modifiers for the Long-QT Syndrome. Circulation: Cardiovascular Genetics, 2016, 9, 330-339.	5.1	21
310	Infanticide vs. inherited cardiac arrhythmias. Europace, 2021, 23, 441-450.	1.7	21
311	Cadherin 2-Related Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003097.	3.6	21
312	Autonomic Nervous System and Arrhythmias. Annals of the New York Academy of Sciences, 1990, 601, 247-262.	3.8	20
313	A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder. Journal of Affective Disorders, 1994, 32, 197-200.	4.1	20
314	Effects of Î²-adrenergic blockade on dispersion of ventricular repolarization in newborn infants with prolonged QT interval. American Heart Journal, 1997, 134, 406-410.	2.7	20
315	Serotonin 1A Receptors, Melatonin, and the Proportional Control Thermostat in Patients With Winter Depression. Archives of General Psychiatry, 1998, 55, 897.	12.3	20
316	Chronic vagal stimulation in patients with congestive heart failure. , 2009, 2009, 2037-9.		20
317	Electrophysiologic mechanisms involved in the development of torsades de pointes. Cardiovascular Drugs and Therapy, 1991, 5, 203-212.	2.6	19
318	The expression of the rare caveolin-3 variant T78M alters cardiac ion channels function and membrane excitability. Cardiovascular Research, 2017, 113, 1256-1265.	3.8	19
319	Idiopathic Long QT Syndrome Exacerbated by Beta-Adrenergic Blockade and Responsive to Left Cardiac Sympathetic Denervation: Implications Regarding Electrophysiologic Substrate and Adrenergic Modulation. Journal of Cardiovascular Electrophysiology, 1992, 3, 295-305.	1.7	18
320	Vagal stimulation for the treatment of heart failure: a translational success story. Heart, 2012, 98, 1687-1689.	2.9	18
321	Rationale and design of a prospective study to assess the effect of left cardiac sympathetic denervation in chronic heart failure. International Journal of Cardiology, 2017, 248, 227-231.	1.7	18
322	Reflex changes in cardiac vagal efferent nervous activity elicited by stimulation of afferent fibres in the cardiac sympathetic nerves. Brain Research, 1972, 42, 482-485.	2.2	17
323	New approaches to antiarrhythmic therapy: emerging therapeutic applications of the cell biology of cardiac arrhythmias. Cardiovascular Research, 2001, 52, 345-360.	3.8	17
324	Ion channel diseases in children: manifestations and management. Current Opinion in Cardiology, 2008, 23, 184-191.	1.8	17

#	Article	IF	Citations
325	Proarrhythmic proclivity of left-stellate ganglion stimulation in a canine model of drug-induced long-QT syndrome type 1. International Journal of Cardiology, 2019, 286, 66-72.	1.7	17
326	Genetics of Peripartum Cardiomyopathy: Current Knowledge, Future Directions and Clinical Implications. Genes, 2021, 12, 103.	2.4	17
327	Practical issues in the management of the long QT syndrome: focus on diagnosis and therapy. Swiss Medical Weekly, 2013, 143, w13843.	1.6	17
328	Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?. European Heart Journal, 2022, 43, 3029-3040.	2.2	17
329	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Journal of Arrhythmia, 2014, 30, 29-47.	1.2	16
330	Long QT syndrome, artificial intelligence, and common sense. European Heart Journal, 2021, 42, 3962-3964.	2.2	16
331	Malignant arrhythmias and acute myocardial ischemia: Interaction between flecainide and the autonomic nervous system. American Heart Journal, 1994, 128, 973-982.	2.7	15
332	New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias. European Heart Journal, 2001, 22, 2148-2163.	2.2	15
333	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. European Heart Journal, 2020, 41, 614-617.	2.2	15
334	The Influence of the Autonomic Nervous System on Sudden Cardiac Death. Cardiology, 1987, 74, 297-309.	1.4	14
335	Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing. American Journal of Cardiology, 1987, 60, 1068-1072.	1.6	14
336	Acquired Long QT Syndrome due to Antiarrhythmic Drugs and Bradyarrhythmias. Annals of the New York Academy of Sciences, 1992, 644, 57-73.	3.8	14
337	When the risk is sudden death, does quality of life matter?. Heart Rhythm, 2016, 13, 70-71.	0.7	14
338	Congenital short QT syndrome. Indian Pacing and Electrophysiology Journal, 2010, 10, 86-95.	0.6	14
339	Tonic afferent sympathetic activity from the heart. Experientia, 1972, 28, 269-270.	1.2	13
340	Role of the autonomic nervous system in reperfusion arrhythmias. Journal of Molecular and Cellular Cardiology, 1988, 20, 113-118.	1.9	13
341	Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey. Clinical Cardiology, 2010, 33, 172-178.	1.8	13
342	Repolarization Abnormalities in the Newborn. Journal of Cardiovascular Pharmacology, 2010, 55, 539-543.	1.9	13

#	Article	IF	Citations
343	Left Cardiac Sympathetic Denervation in Patients with Heart Failure: a New Indication for an Old Intervention?. Journal of Cardiovascular Translational Research, 2014, 7, 338-346.	2.4	13
344	Management of survivors of cardiac arrest â€" the importance of genetic investigation. Nature Reviews Cardiology, 2016, 13, 560-566.	13.7	13
345	Cardiac arrest and Brugada syndrome: Is drug-induced type 1 ECG pattern always a marker of low risk?. International Journal of Cardiology, 2018, 254, 142-145.	1.7	13
346	Abnormal myocardial expression of SAP97 is associated with arrhythmogenic risk. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1357-H1370.	3.2	13
347	There are 100 ways by which the sympathetic nervous system can trigger life-threatening arrhythmias. European Heart Journal, 2020, 41, 2180-2182.	2.2	13
348	Reflex activity of single preganglionic sympathetic fibres during coronary occlusion. Experientia, 1969, 25, 152-153.	1.2	12
349	Carbon monoxide and lethal arrhythmias in conscious dogs with a healed myocardial infarction. American Heart Journal, 1989, 117, 348-357.	2.7	12
350	Parasympathetic control of cycle length dependence of endocardial ventricular repolarisation in the intact feline heart during steady state conditions. Cardiovascular Research, 1993, 27, 823-827.	3.8	12
351	Antifibrillatory efficacy of ersentilide, a novel Î²-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction. Cardiovascular Research, 1998, 40, 56-63.	3.8	12
352	Low-Pass Filtering Approach via Empirical Mode Decomposition Improves Short-Scale Entropy-Based Complexity Estimation of QT Interval Variability in Long QT Syndrome Type 1 Patients. Entropy, 2014, 16, 4839-4854.	2.2	12
353	Lack of correlation between occlusion and reperfusion arrhythmias in the cat. American Heart Journal, 1985, 109, 932-936.	2.7	11
354	Left Cardiac Sympathetic Denervation in Long QT Syndrome Patients. Journal of Interventional Cardiology, 1995, 8, 776-781.	1.2	11
355	Physical Inactivity Is a Risk Factor for Primary Ventricular Fibrillation. Journal of the American College of Cardiology, 2019, 73, 2117-2118.	2.8	11
356	Alpha1-Adrenergic Blockade and Sudden Cardiac Death. Journal of Cardiovascular Electrophysiology, 1994, 5, 76-89.	1.7	10
357	Corrigendum to: 'Recommendations for interpretation of 12-lead electrocardiogram in the athlete' [Eur Heart J 2010;31:243-259]. European Heart Journal, 2010, 31, 379-379.	2.2	10
358	Response by Crotti et al to Letter Regarding Article, â€œGenetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3â€² Untranslated Region of KCNQ1?â€• Circulation: Cardiovascular Genetics, 2016, 9, 581-582.	5.1	10
359	Patient-Specific Induced Pluripotent Stem Cellâ€"Based Disease Model for Pathogenesis Studies and Clinical Pharmacotherapy. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	10
360	Heart Rate Recovery After Exercise Is Associated With Arrhythmic Events in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007471.	4.8	10

#	Article	IF	Citations
361	Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare KCNH2 Variants. Circulation Genomic and Precision Medicine, 2021, 14, e003289.	3.6	10
362	Stress, the autonomic nervous system, and sudden death. Autonomic Neuroscience: Basic and Clinical, 2022, 237, 102921.	2.8	10
363	Clinical applicability of molecular biology: the case of the long QT syndrome. , 2000, 1, 88.		9
364	Mortality due to sudden infant death syndrome in Northern Italy, 1990-2000: a baseline for the assessment of prevention campaigns. Paediatric and Perinatal Epidemiology, 2004, 18, 336-343.	1.7	9
365	Vagal stimulation for heart diseases: from animals to men. An example of translational cardiology. Netherlands Heart Journal, 2013, 21, 82-84.	0.8	9
366	Harmonization of the definition of sudden cardiac death in longitudinal cohorts of the European Sudden Cardiac Arrest network â€“ towards Prevention, Education, and New Effective Treatments (ESCAPE-NET) consortium. American Heart Journal, 2022, 245, 117-125.	2.7	9
367	Evidence for a spinal sympathetic regulation of cardiovascular functions. Experientia, 1970, 26, 965-966.	1.2	8
368	Torsades de Pointes and Ventricular Fibrillation in a Canine Model of Quinidine-induced QT Prolongation. Annals of the New York Academy of Sciences, 1992, 644, 93-102.	3.8	8
369	Cardiac arrhythmias of genetic origin are important contributors to sudden infant death syndrome. Heart Rhythm, 2007, 4, 740-742.	0.7	8
370	Vagal stimulation for heart failure. Current Opinion in Cardiology, 2011, 26, 51-54.	1.8	8
371	The Role of the Cardiac Sodium Channel in Perinatal Early Infant Mortality. Cardiac Electrophysiology Clinics, 2014, 6, 749-759.	1.7	8
372	Neonatal ECG screening: Opinions and facts. Heart Rhythm, 2015, 12, 610-611.	0.7	8
373	Electronic gadgets and their health-related claims. International Journal of Cardiology, 2018, 258, 163-164.	1.7	8
374	Can genetics predict risk for sudden cardiac death? The relentless search for the Holy Grail. European Heart Journal, 2018, 39, 3970-3972.	2.2	8
375	Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: A two-year follow-up. American Heart Journal, 1989, 117, 1258-1264.	2.7	7
376	Mechanistic and Clinical Aspects of Acquired Long QT Syndromes. Annals of the New York Academy of Sciences, 1992, 644, 48-56.	3.8	7
377	Effects of the potassium channel blocking agent ambasilide on ventricular arrhythmias induced by acute myocardial ischemia and sympathetic activation. American Heart Journal, 1995, 129, 549-556.	2.7	7
378	Muscarinic Effects on Action Potential Duration and its Rate Dependence in Canine Purkinje Fibers. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 2023-2026.	1.2	7

#	Article	IF	Citations
379	The Long QT Syndrome: A Clinical Counterpart of hERG Mutations. Novartis Foundation Symposium, 2008, , 186-203.	1.1	7
380	The Unstoppable Attraction for Induced Pluripotent Stem Cells. Journal of the American College of Cardiology, 2012, 60, 1001-1004.	2.8	7
381	Risk factors for primary ventricular fibrillation during a first myocardial infarction: Clinical findings from PREDESTINATION (PRimary vEntricular fibrillation and suDden dEath during firST) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.7	7
382	Outâ€ofâ€hospital cardiac arrest and differential risk of cardiac and nonâ€cardiac QTâ€prolonging drugs in 37â€‰000 cases. British Journal of Clinical Pharmacology, 2022, 88, 820-829.	2.4	7
383	Remote Monitoring of the QT Interval and Emerging Indications for Arrhythmia Prevention. Cardiac Electrophysiology Clinics, 2021, 13, 523-530.	1.7	7
384	A Cellular Basis for the Prolonged QT Interval in Mammals. Annals of the New York Academy of Sciences, 1992, 644, 84-92.	3.8	6
385	Effects of Amiodarone and Bepridil on Ventricular Depolarization and Repolarization. Annals of the New York Academy of Sciences, 1992, 644, 210-222.	3.8	6
386	The Role of the Sympathetic Nervous System in the Long QT Syndrome: The Long Road from Pathophysiology to Therapy. Cardiac Electrophysiology Clinics, 2012, 4, 75-85.	1.7	6
387	Sudden Death by Stress. Journal of the American College of Cardiology, 2014, 63, 828-830.	2.8	6
388	Vox clamantis in deserto. We spoke but nobody was listening: echocardiography can help risk stratification of the long-QT syndrome. European Heart Journal, 2015, 36, 148-150.	2.2	6
389	Regional Lack of Consistency in the Management of Atrial Fibrillation (from the RECORD-AF Trial). American Journal of Cardiology, 2017, 119, 47-51.	1.6	6
390	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1. Stem Cell Research, 2018, 29, 170-173.	0.7	6
391	Congenital Long QT Syndrome. , 2013, , 439-468.		6
392	Molecular genetic testing in athletes: Why and when a position statement from the Italian Society of Sports Cardiology. International Journal of Cardiology, 2022, 364, 169-177.	1.7	6
393	Cardiac Pain, Sympathetic Afferents, and Life-Threatening Arrhythmias. Journal of Cardiovascular Electrophysiology, 1991, 2, s100-s113.	1.7	5
394	Experimental QT Interval Prolongation. Annals of the New York Academy of Sciences, 1992, 644, 74-83.	3.8	5
395	Report from the Task Force of the European Society of Cardiology for the interpretation of the neonatal electrocardiogram. Cardiology in the Young, 2002, 12, 592-608.	0.8	5
396	Sudden Infant Death Syndrome and Cardiac Channelopathies: From Mechanisms to Prevention of Avoidable Tragedies. Neurology International, 2011, 1, e6.	0.5	5

#	Article	IF	Citations
397	The Myth of QT Shortening by Weight Loss and Physical Training in Obese Subjects With Coronary Heart Disease. Obesity, 2011, 19, 200-203.	3.0	5
398	Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine, 2012, 366, 1159-1161.	27.0	5
399	Rapid Recovery of Baroreceptor Reflexes in Acute Myocardial Infarction is a Marker of Effective Tissue Reperfusion. Journal of Cardiovascular Translational Research, 2014, 7, 553-559.	2.4	5
400	MY APPROACH to the long QT syndrome (LQTS). Trends in Cardiovascular Medicine, 2015, 25, 376-377.	4.9	5
401	Sudden Infant Death Syndrome andÂGenetics. Journal of the American College of Cardiology, 2018, 71, 1228-1230.	2.8	5
402	Precision Versus Traditional Medicineâ€"Clinical Questions Trigger Progress in Basic Science. Circulation Research, 2019, 124, 459-461.	4.5	5
403	Management of Congenital Long-QT Syndrome: Commentary From the Experts. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009726.	4.8	5
404	Postnatal development of cardiac innervation and susceptibility to malignant arrhythmias in the dog. Journal of the Autonomic Nervous System, 1990, 30, S153-S154.	1.9	4
405	Pathophysiological mechanisms of sudden infant death syndrome. Cardiology in the Young, 1992, 2, 272-276.	0.8	4
406	Continental Europe triumph in golf competition. Lancet, The, 2002, 360, 468.	13.7	4
407	Cost effectiveness of neonatal ECG screening for the long QT syndrome: reply. European Heart Journal, 2006, 28, 137-139.	2.2	4
408	Introduction to the Arrhythmogenic Disorders of Genetic Origin Series. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 604-605.	4.8	4
409	Autonomic modulation for chronic heart failure: a new kid on the block?. European Journal of Heart Failure, 2012, 14, 1316-1318.	7.1	4
410	Refined multiscale entropy analysis of heart period and QT interval variabilities in long QT syndrome type-1 patients. , 2013, 2013, 5554-7.		4
411	Reply to the Editorâ€" Propranolol Prevents Life-Threatening Arrhythmias in LQT3 Transgenic Mice: Implications for the Clinical Management of LQT3 Patients. Heart Rhythm, 2014, 11, e1-e2.	0.7	4
412	Drug-Induced Long QT Syndrome and Exome Sequencing. Journal of the American College of Cardiology, 2014, 63, 1438-1440.	2.8	4
413	A Refined Multiscale Self-Entropy Approach for the Assessment of Cardiac Control Complexity: Application to Long QT Syndrome Type 1 Patients. Entropy, 2015, 17, 7768-7785.	2.2	4
414	When prescribing drugs, do medical doctors and healthcare professionals realize that their patient has the long QT syndrome?. European Heart Journal, 2019, 40, 3118-3120.	2.2	4

#	Article	IF	Citations
415	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi006-A from a patient affected by an autosomal recessive form of long QT syndrome type 1. Stem Cell Research, 2020, 42, 101658.	0.7	4
416	Prolonged Repolarization and Sudden Infant Death Syndrome. , 2004, , 711-719.		4
417	Abstract 2412: Chronic Vagus Nerve Stimulation in Patients with Chronic Heart Failure is Feasible and Appears Beneficial. Circulation, 2008, 118, .	1.6	4
418	Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19. Frontiers in Physiology, 2021, 12, 730127.	2.8	4
419	Demonstration of a different sensitivity to epinephrine in isolated and in vivo hearts. European Journal of Pharmacology, 1988, 156, 87-94.	3.5	3
420	Tocainide and mortality after myocardial infarction: A prospective study in conscious dogs. Journal of the American College of Cardiology, 1990, 16, 1475-1480.	2.8	3
421	The Sicilian Gambit: a response to Drs Colatsky and Harrison. Cardiovascular Research, 1992, 26, 568-570.	3.8	3
422	Induction of TU Abnormalities in Patients with Torsades de Pointes. Annals of the New York Academy of Sciences, 1992, 644, 178-186.	3.8	3
423	Combined Sodium and Calcium Channel Blockade in Prevention of Lethal Arrhythmias. Journal of Cardiovascular Pharmacology, 2003, 41, 665-670.	1.9	3
424	AB1-5. Heart Rhythm, 2006, 3, S2.	0.7	3
425	From exercise training to sudden death prevention via adrenergic receptors. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2631-H2633.	3.2	3
426	Red BullÂ®: Red flag or red herring?. International Journal of Cardiology, 2017, 231, 179-180.	1.7	3
427	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene. Stem Cell Research, 2018, 29, 157-161.	0.7	3
428	Generation of two human induced pluripotent stem cell (hiPSC) lines from a long QT syndrome South African founder population. Stem Cell Research, 2019, 39, 101510.	0.7	3
429	Prevalence and Phenotypic Correlations of Calmodulinopathy-Causative CALM1-3 Variants Detected in a Multicenter Molecular Autopsy Cohort of Sudden Unexplained Death Victims. Circulation Genomic and Precision Medicine, 2020, 13, e003032.	3.6	3
430	Long and Short QT Syndromes. , 2014, , 935-946.		3
431	Efficacy and Safety of Amiodarone in Treatment of Refractory Atrial and Ventricular Tachyarrhythmias. Annals of the New York Academy of Sciences, 1992, 644, 235-245.	3.8	2
432	Modulation of the Electrical Restitution of Canine Purkinje Fibers by Local Anesthetic Drugs: A Study with Flecainide and Propafenone. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 2074-2078.	1.2	2

#	Article	IF	Citations
433	Gene-specific lethality of arrhythmic events in the long QT syndrome? A message from the International Registry. European Heart Journal, 1999, 20, 1137-1139.	2.2	2
434	Erratum Task Force on Sudden Cardiac Death of the European Society of Cardiology. European Heart Journal, 2002, 23, 257.	2.2	2
435	Response to Letters Regarding Article, â€œClinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervationâ€• Circulation, 2016, 133, e366-7.	1.6	2
436	Long and Short QT Syndromes. , 2018, , 893-904.		2
437	Long QT Syndrome and Sport: My Views. , 2018, , 269-278.		2
438	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi007-A from a Long QT Syndrome type 1 patient carrier of two common variants in the NOS1AP gene. Stem Cell Research, 2019, 36, 101416.	0.7	2
439	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation. Stem Cell Research, 2019, 37, 101431.	0.7	2
440	Cardiac sympathetic denervation via a transtracheal approach: Itâ€™s a long way to Tipperary. Heart Rhythm, 2019, 16, 125-127.	0.7	2
441	PREDESTINATION: PRimary vEntricular fibrillation and suDden dEath during a firST myocardIal iNfArcTION: Genetic Basis. Contributions To Statistics, 2013, , 85-96.	0.2	2
442	The long QT syndrome: a clinical counterpart of hERG mutations. Novartis Foundation Symposium, 2005, 266, 186-98; discussion 198-203.	1.1	2
443	A cardiac murmur depending on the Wolff-Parkinson-White syndrome. American Heart Journal, 1972, 83, 532-534.	2.7	1
444	Denervation of the heart in congenital long QT and deafness. American Journal of Cardiology, 1989, 64, 424.	1.6	1
445	746-1 Antifibrillatory Effect of HE-93, a New K + Channel and Î² Adrenergic Blocker in Conscious Dogs with a Healed Myocardial Infarction. Journal of the American College of Cardiology, 1995, 25, 188A-189A.	2.8	1
446	The ATRAMI Prospective Study: Implications for Risk Stratification after Myocardial Infarction. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 38-40.	1.0	1
447	Electrocardiography first for reducing cot death. Lancet, The, 2001, 358, 672-673.	13.7	1
448	Counting Heart Beats:. Journal of Cardiovascular Electrophysiology, 2003, 14, 174-175.	1.7	1
449	Chronic Vagus Nerve Stimulation (CVNS) - A New Target for Treatment of Congestive Heart Failure. Journal of Cardiac Failure, 2008, 14, S71-S72.	1.7	1
450	Long QT syndrome: from genetic basis to treatment. Neurology International, 2011, 1, .	0.5	1

#	Article	IF	Citations
451	Corrigendum to: 'HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies' [Europace 2011;13:1077-109, doi: 10.1093/europace/eur245]. Europace, 2012, 14, 277-277.	1.7	1
452	Genotype-Phenotype Correlation in Induced Pluripotent Stem Cell (iPSC)Derived Cardiomyocytes Carrying Calmodulin Mutations. Biophysical Journal, 2014, 106, 333a.	0.5	1
453	Time, frequency and information domain analysis of heart period and QT variability in asymptomatic long QT syndrome type 2 patients. , 2015, 2015, 294-7.		1
454	Reply to the Editorâ€"Detection of long QT syndrome in the community. Heart Rhythm, 2015, 12, e67-e68.	0.7	1
455	Difficult management of Jervell and Lange-Nielsen syndrome: An endless search. Heart Rhythm, 2016, 13, 2193-2194.	0.7	1
456	Vagal Stimulation in Heart Failure: An Anti-inflammatory Intervention?. , 2016, , 165-182.		1
457	Founder populations with channelopathies and church records reveal all sorts of interesting secrets: Some are scientifically relevant. Heart Rhythm, 2017, 14, 1882-1883.	0.7	1
458	Evolution in Managing Long QT Syndrome. Journal of the American College of Cardiology, 2017, 70, 463-465.	2.8	1
459	Neural and Spinal Stimulation. , 2017, , 595-601.		1
460	Is Careful Assessment of Rare Variants in the RYR2 Gene Piercing the Guidelinesâ€™ Strong Armor?. Circulation Genomic and Precision Medicine, 2018, 11, e002072.	3.6	1
461	Alberto Zanchetti (27 July 1926). European Heart Journal, 2018, 39, 2344-2345.	2.2	1
462	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi005-A from a patient carrying the KCNQ1-R190W mutation. Stem Cell Research, 2019, 37, 101437.	0.7	1
463	The answers to questions surrounding left cardiac sympathetic denervation are in the library, covered by dust. Heart Rhythm, 2020, 17, 1646-1648.	0.7	1
464	Cardiac Repolarization and Stem Cells: An Emerging Path Toward Precision Medicine. , 2020, , 87-107.		1
465	Genetic Diseases. , 2012, , 875-883.		1
466	Long QT Genotype Can Be Identified by ECG Phenotype. Journal of the American College of Cardiology, 1998, 31, 192A.	2.8	1
467	Can we Modulate the Autonomic Nervous System to Improve the Life of Patients with Heart Failure? The Case of Vagal Stimulation. Arrhythmia and Electrophysiology Review, 2014, 3, 120.	2.4	1
468	The Role of Left Stellectomy in the Prevention of Lethal Arrhythmias. Developments in Cardiovascular Medicine, 1988, , 109-121.	0.1	1

#	Article	IF	Citations
469	Drug-Induced Long QT Syndrome and Torsades de Pointes. , 2020, , 185-200.		1
470	Sudden Cardiac Death in Infancy: Focus on Prolonged Repolarization. , 2008, , 924-933.		1
471	Sudden infant death, long Q-T interval and long Q-T syndrome. American Journal of Medicine, 1977, 62, 164.	1.5	0
472	Comparative Evaluation of Antiarrhythmic Therapy. Drugs, 1985, 29, 86.	10.9	0
473	Mexiletine in the Prevention of Sudden Cardiac Death: Experimental Evaluation and Clinical Implications. Clinical Progress in Electrophysiology and Pacing, 1986, 4, 595-601.	0.1	0
474	Class III Drugs: Their Effects on Arrhythmias and on the QT Interval. Annals of the New York Academy of Sciences, 1992, 644, 223-234.	3.8	0
475	Autonomic Nervous System: Emerging Concepts and Clinical Applications. , 0, , 62-73.		0
476	Response to Letter Regarding Articles, â€œPrevalence of Long QT Syndrome Gene Variants in Sudden Infant Death Syndrome,â€•â€œCardiac Sodium Channel Dysfunction in Sudden Infant Death Syndrome,â€• and â€œContribution of Long-QT Syndrome Genes to Sudden Infant Death Syndrome: Is It Time to Consider Newborn Electrocardiographic Screening?â€• Circulation, 2007, 116, .	1.6	0
477	Inherited Cardiac Arrhythmia Syndrome: Role of Potassium Channels. Cardiac Electrophysiology Clinics, 2011, 3, 113-124.	1.7	0
478	When genetic screening for your patient with long QT syndrome comes back negative, donâ€™t always take a no for a no. Heart Rhythm, 2012, 9, 1983-1985.	0.7	0
479	Filtering approach based on empirical mode decomposition improves the assessment of short scale complexity in long QT syndrome type 1 population. , 2014, 2014, 6671-4.		0
480	163â€…Genetic Modifiers in Carriers of the SCN5A E1784K Mutation with Variable Phenotypic Expression - Long QT3 / Brugada Syndrome Overlap Disease. Heart, 2014, 100, A94.1-A94.	2.9	0
481	Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes Carrying CALM1-F142l Mutation Recapitulate LQTS Phenotype in Vitro. Biophysical Journal, 2016, 110, 263a.	0.5	0
482	Alberto Zanchetti. Hypertension, 2018, 72, 786-787.	2.7	0
483	Bongani Mayosi, 1967â€“2018. European Heart Journal, 2018, 39, 4051-4052.	2.2	0
484	Letter concerning the editorial by Giustetto et al. Int J Cardiol 2018;254:170â€“171. International Journal of Cardiology, 2018, 268, 155.	1.7	0
485	Fear of Sudden Death During Sport Activity and the Long QT Syndrome. , 2022, , 127-137.		0
486	Prolonged Repolarization and Sudden Infant Death Syndrome. Contemporary Cardiology, 2003, , 481-496.	0.1	0

#	Article	IF	Citations
487	The Long QT Syndrome. , 2005, , 665-680.		0
488	Abnormal heart rate control in SCN5Aâ€[Delta]KPQ Mice. FASEB Journal, 2012, 26, 1135.4.	0.5	0
489	Cardiac Channelopathies and Sudden Infant Death Syndrome. , 2013, , 381-394.		0
490	Neural Factors in Sudden Death. , 1984, , 467-471.		0
491	Use of baroreceptor reflex sensitivity in the prediction of risk after myocardial infarction. Developments in Cardiovascular Medicine, 1996, , 77-91.	0.1	0
492	Variable Phenotype of Long QT Syndrome Patients With the Same Genetic Defect. Journal of the American College of Cardiology, 1998, 31, 349A.	2.8	0
493	ECG Repolarization Parameters in LQTS Family Members With Borderline QTc Duration and Cardiac Events. Journal of the American College of Cardiology, 1998, 31, 193A.	2.8	0
494	Cardiac Events in Genotyped Long QT Syndrome Patients. Journal of the American College of Cardiology, 1998, 31, 349A.	2.8	0
495	Prevalence of the Bifid T Waves in Genotyped LQTS Children. Journal of the American College of Cardiology, 1998, 31, 193A.	2.8	0
496	SEVERE CHRONIC STRESS OFTEN PRECEDES IDIOPATHIC VENTRICULAR FIBRILLATION (IVF). Psychosomatic Medicine, 1999, 61, 113-114.	2.0	0
497	Biventricular arrhythmogenic cardiomyopathy: a paradigmatic case. ScienceOpen Research, 2015, .	0.6	0
498	Risk stratification for sudden cardiac death in primary electrical disorders. , 2018, , 2322-2327.		0
499	Monogenic and oligogenic cardiovascular diseases: genetics of arrhythmiasâ€"catecholaminergic polymorphic ventricular tachycardia. , 2018, , .		0
500	Long QT Syndrome. , 2020, , 3-24.		0
501	Frequency Domain Heart Period and QT Interval Variability Markers Are Linked to Arrhythmic Risk in Long QT Syndrome Type 2. , 0, , .		0
502	Neonatal ECG Screening: When Timing Matters. Neonatology, 2020, 117, 764-766.	2.0	0